A case-control study of NAFLD patients highlighted a potentially protective role for the Val227Ala variant of PPARα against obesity compared to subjects with the wild-type receptor (Chen et al., 2008a). This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.